Doctor ZHANG has been engaged in clinical work for pediatric hematologic tumors for over 40 years and has treated thousands of cases of pediatric lymphoma. She has served as a visiting scholar multiple times at St. Jude Children’s Research Hospital in the United States and the Pediatric Oncology Center at Prince of Wales Hospital, The Chinese University of Hong Kong.

She specializes at using the concept of “precision stratified treatment,” where different treatment plans are used for different pathological types and risk factors. The team has achieved cure rates of over 80% for various pathological subtypes of lymphoma (including NHL), with a cure rate of over 90% for Hodgkin’s lymphoma. For refractory and relapsed pediatric lymphoma, she pioneered the use of sequential infusion therapy with CD19/CD20/CD22 CAR-T cells, showing strong treatment effects and gaining recognition from the international academic community.

She has established a comprehensive stratified combined treatment system for refractory and relapsed pediatric lymphoma, integrating traditional chemotherapy with novel targeted therapy and immunotherapy. This approach has enabled more refractory and relapsed patients to achieve high-quality deep remission.